Market Signal Briefing

Ametek (AME - Free Report) came out with quarterly earnings of $1.89 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.66 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +7.39%. A quarter ago, it was expected that this maker of electronic instruments and electromechanical devices would post earnings of $1.68 per share when it actually produced earnings of $1.78, delivering a surprise of +5.95%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Ametek, which belongs to the Zacks Electronics - Testing Equipment industry, posted revenues of $1.89 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.16%. This compares to year-ago revenues of $1.71 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Ametek shares have added about 2.2% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for Ametek?While Ametek has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Ametek was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.88 on $1.9 billion in revenues for the coming quarter and $7.18 on $7.22 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Testing Equipment is currently in the top 9% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the broader Zacks Computer and Technology sector, Dropbox (DBX - Free Report) , has yet to report results for the quarter ended September 2025. The results are expected to be released on November 6.

This online file-sharing company is expected to post quarterly earnings of $0.64 per share in its upcoming report, which represents a year-over-year change of +6.7%. The consensus EPS estimate for the quarter has been revised 3.3% lower over the last 30 days to the current level.

Dropbox's revenues are expected to be $623.49 million, down 2.4% from the year-ago quarter.

Key Takeaways Blackbaud's Q3 EPS rose 11.1% year over year, beating estimates by 2.8%.Revenue slipped 1.9% due to the EVERFI divestiture but exceeded expectations.Margins expanded as operating expenses fell and productivity gains continued.
Blackbaud, Inc. (BLKB - Free Report) reported third-quarter 2025 non-GAAP earnings per share (EPS) of $1.10, which surpassed the Zacks Consensus Estimate by 2.8%. The bottom line increased around 11.1% year over year.

Total revenues decreased 1.9% year over year to $281.1 million. This was due to the divestiture of EVERFI. The top line surpassed the Zacks Consensus Estimate by 0.5%.

The company’s solid results demonstrate disciplined execution and continued productivity gains. Blackbaud is focused on delivering an attractive financial model that balances growth in revenue, earnings and cash flow with a thoughtful and strategic approach to capital allocation. So far this year, the company has repurchased more than 5% of its outstanding common stock.

GAAP recurring revenue declined 1.5% to $275.8 million, primarily due to the divestiture of EVERFI, accounting for 98.1% of total revenue.

Non-GAAP organic revenues were up 5.2% on a reported basis and 4.8% on a constant-currency basis, year over year. Non-GAAP organic recurring revenues rose 5.5% on a reported basis and 5.1% on a constant-currency basis.

After the announcement, shares of the company jumped around 6% in the trading session yesterday. Shares of the company have soared 11.3% in the past six months compared with the Zacks Computer - Software industry's growth of 26.1%.

Image Source: Zacks Investment Research

BLKB’s Margin DetailsNon-GAAP gross margin was 63% compared with 61% a year ago. Total operating expenses fell 2.8% on a year-over-year basis to $112.9 million.
GAAP operating margin increased 500 basis points (bps) to 19.4%.

Non-GAAP operating margin increased 240 bps to 29.9%. Non-GAAP adjusted EBITDA margin was 27.6%.

BLKB’s Balance Sheet & Cash FlowAs of Sept. 30, 2025, Blackbaud had total cash, cash equivalents and restricted cash of $457.4 million compared with $911.8 million as of June 30, 2025. Total debt (including the current portion) as of Sept. 30, 2025, was $1 billion compared with $1.1 billion as of June 30, 2025.

For the third quarter, cash provided by operating activities was $207.5 million compared with $222.4 million in the prior-year quarter. Non-GAAP adjusted free cash outflow was $125.1 million, up $27.5 million in the year-ago quarter.

As of Sept. 30, 2025, Blackbaud had nearly $514 million available under its stock buyback program, which was expanded and renewed in July 2024.
According to current plans, the company expects total share repurchases in 2025 to represent between 5.2% and 7.0% of its outstanding common stock as of Dec. 31, 2024.

BLKB Provides 2025 OutlookBlackbaud reiterated its guidance for full-year 2025. The company projects GAAP revenues between $1.120 billion and $1.130 billion, reflecting approximately 5% organic growth at the midpoint on a constant currency basis. This represents a $5 million increase, driven by strong transactional revenue in the first half of the year and favorable foreign exchange impacts compared to initial expectations. The Zacks Consensus Estimate is pegged at $1.13 billion.

The company still projects non-GAAP adjusted EBITDA margin in the range of 35.4-36.2%. Non-GAAP EPS is anticipated to be between $4.30 and $4.50. The Zacks Consensus Estimate for EPS is pegged at $4.40.

Non-GAAP adjusted free cash flow for 2025 is forecasted to be in the range of $195-$205 million compared with $190-$200 million projected earlier.

Non-GAAP annualized effective tax rate is still anticipated to be approximately 24.5%. Interest expense is expected in the band of $66 million to $70 million.
Fully diluted shares are still estimated to be 48.5 million to 49.5 million. Capital expenditures are expected to be in the range of $55 million to $65 million, which includes $50-$60 million of capitalized software and content development costs.

Recent UpdatesBlackbaud unveiled a wide range of new embedded AI capabilities across its product portfolio at bbcon 2025, marking a major step toward its vision for a new era of intelligent action. Also, the company announced significant enhancements to Blackbaud Impact Edge, introducing smarter AI features, advanced analytics and measurement tools, and deeper data insights.

Additionally, Blackbaud launched its 2025 Ultimate End-of-Year Fundraising Toolkit, a comprehensive resource designed to help organizations maximize fundraising success. The Blackbaud Institute, in partnership with GivingTuesday, released a new report highlighting the long-term impact of GivingTuesday donors and offering strategies for nonprofits to foster stronger, year-round engagement.

BLKB’s Zacks RankBlackbaud currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Recent Performance of Other FirmsCadence Design Systems (CDNS - Free Report) reported third-quarter 2025 non-GAAP earnings per share of $1.93, which beat the Zacks Consensus Estimate by 7.8%. The bottom line increased 17.7% year over year, exceeding management’s guided range of $1.75-$1.81.

Revenues of $1.339 billion beat the Zacks Consensus Estimate by 0.9% and increased 10.2% year over year. The figure also beat the management’s guided range of $1.305-$1.335 billion.

SAP SE (SAP - Free Report) reported third-quarter 2025 non-IFRS earnings of €1.59 ($1.86) per share, climbing 29% from the year-ago quarter’s levels. The Zacks Consensus Estimate was pegged at $1.69. Driven by robust cloud growth, disciplined cost control and expanding AI capabilities, SAP reported total revenues on a non-IFRS basis of €9.08 billion ($10.6 billion), representing a 7% year-over-year increase (up 11% at constant currency or cc). The Zacks Consensus Estimate was pegged at $10.56 billion.

Badger Meter, Inc. (BMI - Free Report) reported EPS of $1.19 for third-quarter 2025, which surpassed the Zacks Consensus Estimate by 7.2%. Also, the bottom line compared favorably with the year-ago quarter’s EPS of $1.08. Quarterly net sales were $235.7 million, up 13.1% from $208.4 million in the year-ago quarter, driven by higher utility water sales. The Zacks Consensus Estimate was pegged at $229.4 million.

BELGRADE, Mont., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced that it will release financial results for the third quarter ended September 30, 2025 on Thursday, November 6, 2025, after the market close.

Management will conduct an investor conference call on Thursday, November 6 at 5:00 p.m. Eastern Time (3:00 p.m. Mountain Time) to discuss these results and the business outlook. Interested parties can access the conference call by dialing 1-800-343-4136 or 1-203-518-9843. The conference call will also be broadcast live on the Investor Relations section of our website at https://ir.bridgeraerospace.com.

An audio replay will be available through November 13, 2025, by calling 844-512-2921 or 412-317-6671 and using the passcode 11160179. The replay will also be accessible at https://ir.bridgeraerospace.com.

Sidoti Investor Conference – December 10 and 11
The Company also announced that management is scheduled to participate in the Sidoti Year End Virtual Investor Conference on December 10 and 11, 2025. The live, interactive webcast and slide presentation is scheduled for 4:00 PM ET on December 10 and will be accessible from the investors section of the Bridger Aerospace website at https://ir.bridgeraerospace.com/news-events/ir-calendar.

The company will also host virtual one-on-one meetings throughout both days of the conference. Registration for the presentation and the one-on-ones will be available at the Sidoti event site at www.sidoti.com/events.

About Bridger Aerospace
Based in Belgrade, Montana, Bridger Aerospace Group Holdings, Inc. is one of the nation’s largest aerial firefighting companies. Bridger provides aerial firefighting and wildfire management services to federal and state government agencies, including the United States Forest Service, across the nation, as well as internationally. More information about Bridger Aerospace is available at https://www.bridgeraerospace.com.

Investor Contacts
Alison Ziegler
Darrow Associates
201-220-2678
[email protected]

Standard Chartered PLC (SCBFF - Free Report) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.39 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +13.33%. A quarter ago, it was expected that this company would post earnings of $0.6 per share when it actually produced earnings of $0.74, delivering a surprise of +23.33%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Standard Chartered, which belongs to the Zacks Banks - Foreign industry, posted revenues of $5.11 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.75%. This compares to year-ago revenues of $4.95 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Standard Chartered shares have added about 64.5% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for Standard Chartered?While Standard Chartered has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Standard Chartered was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.24 on $4.59 billion in revenues for the coming quarter and $2.13 on $20.46 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Foreign is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Credicorp (BAP - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025.

This Peruvian finance company is expected to post quarterly earnings of $6.05 per share in its upcoming report, which represents a year-over-year change of +19.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Credicorp's revenues are expected to be $1.59 billion, up 14.4% from the year-ago quarter.

Daily Gold (XAU/USD)
From a price structure standpoint, gold’s ability to hold above $3886.46 is key. The level is just above the 50-day moving average and 50% retracement zone — both of which have anchored bullish momentum since August 22. If bulls defend this base, the rebound rally has technical room to extend toward the 50% level at $4133.95. A break below $3807.38, however, would expose gold to deeper liquidation.

US-China Trade Deal Adds Uncertainty, Not Confidence
Gold’s upside is also being shaped by skepticism around the Trump-Xi trade announcement. Trump claimed a tariff rollback in exchange for Chinese commitments on soybeans, rare earth exports, and fentanyl enforcement, but Beijing has yet to confirm key details. Traders remain cautious, recalling past reversals in similar trade negotiations.

That uncertainty is helping keep safe haven demand alive, even as broader risk sentiment remains mixed. Meanwhile, the Bank of Japan’s decision to hold rates and offer little guidance weighed on the yen, boosting the dollar slightly, but not enough to offset gold’s broader rate-driven support.

Gold Price Forecast: Bias Remains Bullish Above $3807.38
As long as spot gold holds above the 50-day moving average at $3807.38, the technical bias favors a continuation of the rebound toward $4133.95. The fundamental backdrop — a cautious Fed, uncertain trade outlook, and a softening dollar — supports this view. A decisive break below $3807.38 would shift the bias bearish and signal potential for deeper correction. Traders will watch Friday’s inflation data and updated rate cut odds closely.

October 30, 2025 08:07 ET

 | Source:

Freddie Mac

MCLEAN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Freddie Mac (OTCQB: FMCC) today reported its Third Quarter 2025 financial results and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission. The company’s Form 10-Q and earnings press release, along with the Third Quarter 2025 financial results supplement are available now on the Investor Relations page of the company’s website.

The company will hold a call at 9 a.m. Eastern Time (ET) today, October 30, 2025, to share its results with the media. The call will be concurrently webcast, and the replay will be available on the company’s website for approximately 30 days.

Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability and affordability in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn More: Website | Consumers | X | LinkedIn | Facebook | Instagram | YouTube

MEDIA CONTACT: Frederick Solomon
703-903-3861
[email protected]  

INVESTOR CONTACT: Mahesh Lal
571-382-3630

With the proliferation of artificial intelligence (AI) and the data storage it requires, numerous industries are emerging as pick-and-shovel plays by providing essential ancillary services for the emerging technology. Those span industries from data centers and utility companies to electric infrastructure and cloud storage.

HomeIndustriesPharmaceuticalsEarnings ResultsEarnings ResultsRevenue climbs more than 50% to beat expectations by a wide margin as demand for GLP-1 drugs are still boomingPublished: Oct. 30, 2025 at 8:09 a.m. ET

Shares of Eli Lilly surged in early Thursday trading, as the drugmaker reported huge demand for its GLP-1 weight-loss and diabetes drugs, leading to record revenue and a raised full-year outlook.

The drug giant also highlighted the progress it has made with its oral obesity and diabetes treatment orforglipron, which produced positive results from four late-stage trials. The company plans to move along with the approval process by submitting the drug candidate to regulatory authorities by the end of the year.

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)---- $KRMN #aerospace--Karman Space & Defense Acquires Five Axis Industries Inc., a Leading Supplier of Advanced Engine Subsystems for Major Commercial Space Programs.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

KBR Inc. (KBR - Free Report) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.95 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +7.37%. A quarter ago, it was expected that this the engineering, construction company would post earnings of $0.88 per share when it actually produced earnings of $0.91, delivering a surprise of +3.41%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

KBR, which belongs to the Zacks Engineering - R and D Services industry, posted revenues of $1.93 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.29%. This compares to year-ago revenues of $1.95 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

KBR shares have lost about 26% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for KBR?While KBR has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for KBR was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.02 on $2.06 billion in revenues for the coming quarter and $3.77 on $8.03 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Engineering - R and D Services is currently in the top 24% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Amentum Holdings (AMTM - Free Report) , is yet to report results for the quarter ended September 2025. The results are expected to be released on November 25.

This government services company is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of +25.5%. The consensus EPS estimate for the quarter has been revised 6.5% higher over the last 30 days to the current level.

Amentum Holdings' revenues are expected to be $3.61 billion, up 63.1% from the year-ago quarter.

LXP Industrial (LXP - Free Report) came out with quarterly funds from operations (FFO) of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to FFO of $0.16 per share a year ago. These figures are adjusted for non-recurring items.

A quarter ago, it was expected that this real estate investment trust would post FFO of $0.16 per share when it actually produced FFO of $0.16, delivering no surprise.

Over the last four quarters, the company has not been able to surpass consensus FFO estimates.

LXP Industrial, which belongs to the Zacks REIT and Equity Trust - Residential industry, posted revenues of $86.9 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 1.83%. This compares to year-ago revenues of $85.57 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

LXP Industrial shares have added about 17.2% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for LXP Industrial?While LXP Industrial has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for LXP Industrial was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $0.16 on $88.81 million in revenues for the coming quarter and $0.63 on $353.91 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Residential is currently in the bottom 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

UMH Properties (UMH - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2025. The results are expected to be released on November 3.

This real estate investment trust is expected to post quarterly earnings of $0.25 per share in its upcoming report, which represents a year-over-year change of +4.2%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

UMH Properties' revenues are expected to be $68.9 million, up 13.6% from the year-ago quarter.

Integra LifeSciences (IART - Free Report) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.41 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +25.58%. A quarter ago, it was expected that this medical device maker would post earnings of $0.43 per share when it actually produced earnings of $0.45, delivering a surprise of +4.65%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Integra, which belongs to the Zacks Medical - Instruments industry, posted revenues of $402.06 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 3.07%. This compares to year-ago revenues of $380.83 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Integra shares have lost about 32% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for Integra?While Integra has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Integra was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.93 on $457.68 million in revenues for the coming quarter and $2.21 on $1.67 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, ClearPoint Neuro, Inc. (CLPT - Free Report) , has yet to report results for the quarter ended September 2025.

This company is expected to post quarterly loss of $0.20 per share in its upcoming report, which represents a year-over-year change of -11.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

ClearPoint Neuro, Inc.'s revenues are expected to be $9.9 million, up 21.9% from the year-ago quarter.

Lakeland Industries (LAKE - Free Report) is a Zacks Rank #1 (Strong Buy) that has a D for Value and a D for Growth. This company makes suits used in clean ups big and small.  Their products range from toxic waste clean up garments to Fireland Fyrepel products that are used for fire and heat protection.  The company also makes special safety gloves and medical woven cloth garments.  Let’s learn more about why this stock is the Bull of the Day.

Description                                              

Lakeland Industries, Inc. engages in the manufacture and sale of safety garments and accessories for the industrial and public protective clothing market. It operates through the Domestic and International geographical segments. The firm's products include disposable protective clothing, chemical protective clothing, woven protective clothing, fire protective gear, heat protective clothing, reflective protective clothing, hand and arm protection, arc or fire-retardant rated rainwear, and fire-retardant protective clothing. The company was founded in April 1982 and is headquartered in Huntsville, AL.

Earnings History                                                         

When I look at a stock, the first thing I do is look to see if the company is beating the number.  This tells me right away where the market’s expectations have been for the company and how management has communicated to the market.  A stock that consistently beats has management communicating expectations to Wall Street that can be achieved.  That is what you want to see.

Lakeland Industries (LAKE ) has missed the Zacks Consensus Estimate in three of the last four quarters. The company most recently posted EPS of $0.36 per share when the Zacks Consensus Estimate was calling for a loss of $0.04.  That 40 cent beat translates into a 1000% positive earnings surprise.

Over the last four quarters the average positive surprise works out to be 106%.

Earnings Estimates Revisions

Earnings estimate revisions is what the Zacks Rank is all about. 

Estimates are moving higher for Lakeland Industries (LAKE - Free Report) .

The full year 2025 has increased from $0.18 to $0.50 over the last 60 days.

2026 has increased from $1.23 to $1.28 over the same time period.

Growth

There is good growth projected for Lakeland Industries (LAKE - Free Report) .  This fiscal year analysts are expecting $213M in revenue which would be good for 27% topline growth.

Next fiscal year, the consensus is calling for $240 M and that would be good for 12.7% sales growth.

Valuation

The valuation for Lakeland Industries (LAKE - Free Report) is compelling in terms of price to book.  I see a price to book multiple of 1.06x which means investors are barely paying a premium over the cost of the assets on hand.  The forward PE if 32x is a little high, but the growth the company is expected to show makes up for that high multiple.  Price to sales comes in at 0.82x which suggests the market doesn’t give the company full credit for each dollar of sales the company posts.  Part of the reason for that is the negative operating margins the company has shown over the last few quarters.

Management to host Investor Conference Call at 8:30 a.m. ET on the same day to discuss results

, /PRNewswire/ -- Ceragon (NASDAQ: CRNT), a leading solutions provider of end-to-end wireless connectivity, announces that it will release its earnings results for the third quarter ended September 30, 2025 on Tuesday, November 11, 2025, before the market opens.

The Company will hold a Zoom webcast at 8:30 a.m. ET that same day to review the results, which will include a Q&A session. Investors may register for the call by clicking here. All relevant access details will be provided upon registration.

For those unable to join the live call, a replay will be available on the Company's website at www.ceragon.com.

About Ceragon

Ceragon (NASDAQ: CRNT) is the global innovator and leading solutions provider of end-to-end wireless connectivity, specializing in transport, access, and AI-powered managed & professional services. Through our commitment to excellence, we empower customers to elevate operational efficiency and enrich the quality of experience for their end users.

Our customers include service providers, utilities, public safety organizations, government agencies, energy companies, and more, who rely on our wireless expertise and cutting-edge solutions for 5G & 4G broadband wireless connectivity, mission-critical services, and an array of applications that harness our ultra-high reliability and speed. Ceragon solutions are deployed by more than 600 service providers, as well as more than 1,600 private network owners, in more than 130 countries. Through our innovative, end-to-end solutions, covering hardware, software, and managed & professional services, we enable our customers to embrace the future of wireless technology with confidence, shaping the next generation of connectivity and service delivery. Ceragon delivers extremely reliable, fast to deploy, high-capacity wireless solutions for a wide range of communication network use cases, optimized to lower TCO through minimal use of spectrum, power, real estate, and labor resources - driving simple, quick, and cost-effective network modernization and positioning Ceragon as a leading solutions provider for the "connectivity everywhere" era.

For more information please visit: www.ceragon.com

Ceragon Networks® and FibeAir® are registered trademarks of Ceragon Networks Ltd. in the United States and other countries. CERAGON® is a trademark of Ceragon, registered in various countries. Other names mentioned are owned by their respective holders.

Investor Contact:

Rob Fink
FNK IR
1+646-809-4048

Joey Delahoussaye
FNK IR
1+312-809-1087

[email protected]

Logo - https://mma.prnewswire.com/media/1704355/Ceragon_Networks_Ltd_Logo.jpg

SOURCE Ceragon Networks Ltd.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

October 30, 2025 7:00 AM EDT | Source: PreveCeutical Medical Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche") of its previously announced $1,200,000 non-brokered private placement (the "Offering"), which Second Tranche consisted of the issuance of 11,375,000 units (each, a "Unit") of the Company at a price of $0.04 per Unit for gross aggregate proceeds of $455,000.

Each Unit is comprised of one (1) common share (each, a "Share") in the capital of the Company and one-half (1/2) of one Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder thereof to purchase an additional Share (each, a "Warrant Share") at an exercise price of $0.06 per Warrant Share for a period of 24 months from the closing of the Second Tranche (the "Second Tranche Closing"), subject to an acceleration right, whereby the expiry date of the Warrants may be accelerated if the daily closing price of the Shares equals or exceeds $0.18 or greater on the Canadian Securities Exchange ("CSE") (or such other recognized securities exchange on which the Shares may then trade) for a minimum of ten consecutive trading days, in which event the Company may accelerate the expiry of the Warrants by giving notice via news release and, in such case, all of the then unexercised Warrants will expire on the 30th day after the date on which the news release is disseminated (the "Acceleration Right").

In connection with the Second Tranche Closing, the Company paid finders fees to three eligible finders comprised of $29,200 in cash and issued 730,000 finder's Warrant (each, a "Finder's Warrant"). The Finder's Warrant are exercisable into one additional Share at an exercise price of $0.06 per Share for 24 months from the Second Tranche Closing, subject to the Acceleration Right.

The Company intends to use the aggregate gross proceeds of the Second Tranche to pay outstanding payables, for operating expenses and for general working capital purposes.

All securities issued in relation to the Second Tranche are subject to a hold period expiring four months and one day after the Second Tranche Closing, in accordance with applicable securities laws.

The securities issued under the Offering, including those in the Second Tranche, have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the use of proceeds of the Second Tranche and the closing of a subsequent tranche of the Offering. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that the proceeds of the Second Tranche may not be used as stated in this news release, that the Company may not be able to close a subsequent tranche of the Offering and those additional risks set out in the Company's public documents filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272529

WASHINGTON--(BUSINESS WIRE)--FiscalNote Holdings, Inc. (NYSE: NOTE), the leading provider of AI-driven policy and regulatory intelligence solutions, today announced it will report financial results for the Third Quarter ended September 30, 2025, on Thursday, November 6, 2025, immediately following market close. The Company will also conduct a related conference call at 5:00 p.m. ET (U.S.) on that same day. Information regarding how to participate in the conference call is provided below.

Conference Call Information:

LIVE

Via Phone

For the U.S. or Canada, dial 1 (800) 715-9871; for International, dial (646) 307-1963. Enter conference ID 7871199.

Via Webcast

Visit the Investor Relations section of the Company’s website.

REPLAY

Via Phone

For the U.S. or Canada: dial 1 (800) 770-2030; for International: dial (609) 800-9099. Enter conference ID 7871199. (Replay available through Thursday, November 13, 2025).

Via Webcast

Visit the Investor Relations section of the Company’s website. (Webcast is archived indefinitely).

About FiscalNote

FiscalNote (NYSE: NOTE) is the leading SaaS provider of policy and regulatory intelligence. By uniquely combining proprietary AI technology, comprehensive data, and decades of trusted analysis, FiscalNote helps customers manage political and business risk. Since 2013, FiscalNote has pioneered solutions that deliver critical insights, enabling efficient decision making and giving organizations the competitive edge they need. Home to PolicyNote, CQ, Roll Call, VoterVoice, and many other industry-leading products and brands, FiscalNote serves thousands of customers worldwide with global offices in North America, Europe, and Asia. To learn more about FiscalNote and its suite of solutions, visit FiscalNote.com and follow @FiscalNote.

Investors must own AMPG Common stock by the close of Nasdaq trading on Friday, November 7, 2025 to be a Record Date holder

Hauppauge, NY, October 30, 2025 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company” or “AmpliTech”), a leading designer and manufacturer of advanced signal-processing components for satellite, 5G/6G networks, and quantum systems, today announced that it intends to offer to its shareholders and certain warrantholders a dividend in the form of a transferable unit subscription right ( “Unit Rights”) to participate in the unit rights offering.

AmpliTech has an effective Form S-3 base prospectus from which it intends to offer these securities registered with the Securities and Exchange Commission (the “SEC”) for a proposed rights offering in which it plans to distribute to (a) stockholders and (b) certain warrantholders two transferable Unit Rights to purchase up to the maximum of 8,000,000 units at $4.00 per unit. Each unit will consist of one share of common stock (the “Common Shares”) and two short-term rights to purchase additional Common Shares.

Under the rights offering, each stockholder and certain warrant holders as of the record date will receive, as a dividend, at no charge, two Unit Rights for each (a) Common Share and (b) each Common Share subject to a Warrant owned on the record date. The distribution of the Unit Rights will occur on or around the record date. The record date for the distribution of the Unit Rights, the expiration dates for the Unit Rights and related short-term rights, and related pricing information will be included in the final prospectus.

Holders who fully exercise their Unit Rights will be entitled to oversubscribe for additional units, if available, that are not purchased by other right holders, subject to potential pro rata allocation of those over-subscription units for which they subscribe in proportion to the total number of over-subscription units.

AmpliTech intends to use the net proceeds of the rights offering to scale domestic manufacturing and operations; advance R&D and product commercialization; deepen vertical integration and supply-chain resilience; engage in strategic partnerships; and support corporate growth initiatives; and for working capital and general corporate purposes. The Company recommends that current shareholders and certain warrant holders notify their broker or financial advisor about the upcoming rights offering to ensure their ability to participate.

The expected calendar for the rights offering is as follows:

 DatesOwnership date (last day to buy AMPG to become Record date holder)November 7, 2025Record dateNovember 10, 2025Commencement dateNovember 11, 2025 UNIT RIGHTS Deadline for delivery of subscription and payment of unit subscription priceDecember 10, 2025Expiration date for Subscription RightsDecember 10, 2025Extension period (if any)January 9, 2026   SERIES RIGHTS Series A Rights Subscription Price of $5.00 per share Deadline for delivery of subscription and payment of exercise priceJuly 18, 2026Expiration date for Series A RightsJuly 18, 2026 Series B Rights Subscription Price of $6.00 per share Deadline for delivery of subscription and payment of exercise priceNovember 20, 2026Expiration date for Series B RightsNovember 20, 2026
Please contact our information agent MacKenzie Partners, Inc. if you have questions about the rights offering or need copies of the prospectus at [email protected].

AmpliTech has engaged Moody Capital Solutions, Inc. to act as dealer-manager for the rights offering. Broker dealers, registered investment advisors and institutions may contact Moody at [email protected].

AmpliTech reserves the right to terminate the proposed rights offering at any time prior to the expiration date and for any reason. A prospectus relating to these securities will be filed with the SEC. This announcement shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state. Securities of AmpliTech are NSMIA exempt. A security that is NSMIA exempt is classified as a “covered security” under the National Securities Markets Improvement Act of 1996 and is therefore exempt from state-level registration and regulation, subject only to federal oversight through the SEC. The rights offering will be made only by means of a prospectus.

About AmpliTech Group, Inc.

AmpliTech Group, Inc., is comprised of five divisions, AmpliTech Inc., Specialty Microwave, Spectrum Semiconductors Materials, AmpliTech Group Microwave Design Center, and AmpliTech Group True G Speed Services, is a leading designer, developer, manufacturer, and distributor of cutting-edge radio frequency (RF) microwave components and 5G network solutions. Serving global markets including satellite communications, telecommunications (5G & IoT), space exploration, defense, and quantum computing, AmpliTech Group is committed to advancing technology and innovation. For more information, please visit our website at www.amplitechgroup.com or amplitech5G.com.

About Moody Capital Solutions, Inc.

Moody Capital Solutions, Inc. has cultivated and actively maintains deep relationships across a wide network of institutional investors, top-tier law firms, and investor relations specialists. These connections empower it to deliver unmatched advisory services and seamless transaction execution. At Moody Capital, every client engagement is led directly by senior bankers—from strategy to closing. Unlike larger firms, it does not delegate execution to junior staff. Moody Capital is a relationship-driven investment bank committed to delivering high-touch, high-quality results. Moody Capital senior bankers collectively have more than 150 years of investment banking experience. Moody Capital senior bankers have worked at some of the leading large-cap and small-cap investment banks in the U.S.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements. These statements appear in several places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things, that the Company will close and be successful in raising capital in connection with the rights offering. The words “may” “would” “will” “expect” “estimate” “anticipate” “believe” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements because of various factors. Other risks are identified and described in more detail in the “Risk Factors” section of the Company’s filings with the SEC, which are available on our website and with the SEC at www.sec.gov. We undertake no obligation to update, and we do not have a policy of updating or revising these forward-looking statements, except as required by applicable law.

Contacts:

Corporate Social Media
X: @AmpliTechAMPG 
Instagram: @AmpliTechAMPG
Facebook: AmpliTechInc
LinkedIn: AmpliTech Group Inc

Company Contact:
Jorge Flores
Tel: 631-521-7831
[email protected]

Investor Relations Contact:
Kirin Smith
[email protected]

Source: AmpliTech Group 

Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured at the headquarters in Le Passage, near Agen, France March 29, 2018. REUTERS/Regis Duvignau/File Photo Purchase Licensing Rights, opens new tab

CompaniesOct 30 (Reuters) - Bristol Myers Squibb

(BMY.N), opens new tab beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a hit from generic competition for several older drugs.

Bristol Myers also raised its full-year revenue forecast, reflecting optimism that its portfolio of recently launched drugs will plug a multibillion-dollar revenue gap from patent expirations that open several best-selling drugs to competition. CEO Christopher Boerner has also aggressively pursued acquisitions and partnerships to fill Bristol Myers' pipeline.

Sign up here.

For the third quarter, Bristol Myers posted revenue of $12.22 billion, beating analysts' average estimate of $11.8 billion, according to data compiled by LSEG.

On an adjusted basis, the company earned $1.63 per share, compared with estimates of $1.51 per share.

Sales of its top cancer immunotherapy, Opdivo, rose 7% to $2.53 billion, and the newer subcutaneously injected version of the drug added another $67 million. That compares with analyst expectations of $2.2 billion.

Bristol Myers Chief Commercialization Officer Adam Lenkowsky said in an interview that the company still expects to convert 30% to 40% of its Opdivo sales to the subcutaneous version before the drug's patent expires.

Sales of blood thinner Eliquis, which Bristol Myers shares with Pfizer

(PFE.N), opens new tab, jumped 25% to $3.75 billion, compared with Wall Street estimates of $3.4 billion.

Revenue from the company's "growth portfolio," which includes Opdivo and new products like heart drug Camzyos, rose 18% to $6.9 billion, helping to offset a 59% plunge in sales of blood cancer treatment Revlimid, its one-time top-selling drug, to $575 million.

Bristol Myers now expects full-year earnings in the range of $47.5 billion to $48 billion, up from its previous forecast of $46.5 billion to $47.5 billion.

Bristol has been contending with a steep revenue decline from Revlimid, which raked in nearly $13 billion in 2021 but only $5.8 billion last year due to generic competition. Some of its other cancer drugs such as Pomalyst, Sprycel and Abraxane are contending with the same issue.

The company is also under pressure from the Trump administration to lower drug prices. President Donald Trump has unveiled deals in recent weeks with Pfizer Inc

(PFE.N), opens new tab and UK-based drugmaker AstraZeneca

(AZN.L), opens new tab under which the companies will sell some medicines at a discount to Medicaid, the government health plan for low-income people, in exchange for tariff relief.

"We continue to engage with the administration," Lenkowsky said.

Reporting by Michael Erman; Editing by Leslie Adler

Our Standards: The Thomson Reuters Trust Principles., opens new tab

-

IonQ executives highlight the company’s latest quantum advancements underscoring progress around the UK's collaborative quantum strategy

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its participation in the 2025 UK National Quantum Technologies Showcase, taking place on November 7th at the Business Design Centre in London. Organized by Innovate UK in collaboration with the Engineering and Physical Sciences Research Council (EPSRC) and the UK National Quantum Technologies Programme (UKNQTP), it is one of the largest quantum events in the UK, convening more than 2,000 stakeholders across government, academia, and industry.

“We are delighted to demonstrate our latest advancements in quantum computing innovation at the UK Quantum Showcase this year. The UK has long held a leading position in quantum technologies due to its world-class science and research base,” said Dr. Chris Ballance, President of Quantum Computing at IonQ and co-founder of Oxford Ionics. “The strength of the UK’s technological leadership helped us achieve the highest-performing quantum platform available on the market."

IonQ’s presence at the showcase follows a landmark year for the company in the UK, including the designation of Oxford as IonQ’s EMEA headquarters, its acquisition of Oxford Ionics, and the delivery of Quartet, a quantum computing testbed for the UK’s National Quantum Computing Centre (NQCC). These milestones reinforce IonQ’s role as a key player in advancing the UK’s national quantum strategy as it accelerates the commercial use of quantum technologies.

IonQ will host booth #52 where participants will explore the company’s latest quantum innovations.

About IonQ

IonQ, Inc. [NYSE: IONQ] is the world’s leading quantum company delivering solutions to solve the world’s most complex problems. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results.

The company is accelerating its technology roadmap and intends to deliver the world’s most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ’s advancements in quantum networking also position the company as a leader in building the quantum internet.

The company’s innovative technology and rapid growth were recognized in Fortune Future 50, Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, and Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature are intended to identify forward-looking statements. These statements include those related to the scalability, fidelity, efficiency, viability, accessibility, effectiveness, reliability, performance, speed, and commercial-readiness of IonQ’s offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ’s ability to deliver, and customers’ ability to generate, value from IonQ’s offerings; IonQ’s ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ’s ability to effectively integrate its acquisitions of Oxford Ionics Limited; changes in laws and regulations affecting IonQ’s patents; and IonQ’s ability to maintain or obtain patent protection for its products and technology, including with sufficient breadth to provide a competitive advantage. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ's filings with the U.S. Securities and Exchange Commission, including but not limited to the Company's most recent Annual Report on Form 10-K and reports on Form 10-Q. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

More News From IonQ, Inc.

Back to Newsroom

October 30, 2025 07:05 ET

 | Source:

Zhihu Inc.

BEIJING, China, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that it will report its unaudited financial results for the quarter ended September 30, 2025 before the U.S. market opens on November 25, 2025.

The Company’s management will host a conference call at 6:00 A.M. U.S. Eastern Time on Tuesday, November 25, 2025 (7:00 P.M. Beijing/Hong Kong Time on Tuesday, November 25, 2025) to discuss the results.

All participants wishing to join the conference call must pre-register online using the link provided below. Once the pre-registration has been completed, each participant will receive a set of dial-in numbers and a unique access PIN which can be used to join the conference call.

Registration Link: https://register-conf.media-server.com/register/BId01f39d00a68420ba15e28d3dc711d2d

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at https://ir.zhihu.com.

About Zhihu Inc.

Zhihu Inc. (NYSE: ZH; HKEX: 2390) is a leading online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Since the initial launch in 2010, Zhihu has grown into the largest Q&A-inspired online content community in China. For more information, please visit https://ir.zhihu.com.

For investor and media inquiries, please contact:

Zhihu Inc.
Email: [email protected]

Christensen Advisory
Roger Hu
Tel: +86-10-5900-1548
Email: [email protected]

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales
Received 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN
Reported EMPAVELI U.S. net product revenue of $27 million, reflecting strong early launch in C3G and primary IC-MPGN and continued high patient compliance in PNH
SYFOVRE® (pegcetacoplan injection) total injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $151 million
Cash and cash equivalents of $479 million as of September 30, 2025; existing cash expected to be sufficient to fund business to sustainable profitability
Management to host conference call today at 8:30 a.m. ET WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its third quarter 2025 financial results and business highlights.

“The third quarter was marked by strong execution and meaningful progress across our commercial and development portfolio. We were thrilled to receive our third regulatory approval in just four years, introducing a first-in-class C3 therapy for patients with C3G and primary IC-MPGN, many of whom previously had no available treatment options. The positive reception from the nephrology community reflects recognition of EMPAVELI’s compelling efficacy and safety profile, and strengthens our confidence in its potential to become the treatment of choice for patients,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis. “At the same time, SYFOVRE continues to lead the geographic atrophy market and deliver a steady, durable revenue stream that supports our long-term growth ambitions. Combined with our strong financial position, these achievements enable us to enter the fourth quarter and 2026 with a solid foundation and clear momentum for continued growth.”

Third Quarter 2025 Business Highlights and Upcoming Milestones

Maximizing EMPAVELI’s impact in rare diseases

Recorded $26.8 million in EMPAVELI U.S. net product revenue for the third quarter 2025.C3 glomerulopathy (C3G) and primary immune complex glomerulonephritis (IC-MPGN): On July 28, 2025, EMPAVELI was approved by the U.S. Food and Drug Administration (FDA) as the first treatment for C3G and primary IC-MPGN for patients 12 and older. Approval was based on the trifecta of positive outcomes in the Phase 3 VALIANT study including a 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits as measured by C3 staining, compared to placebo.Launch is underway with 152 patient start forms received as of September 30, 2025. This number includes approximately 50 patients from the Company’s early access program who are in the process of transitioning to commercial product.Sobi, the Company’s ex-U.S. commercialization partner, expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its indication extension application for Aspaveli (the brand name for EMPAVELI outside the U.S.) in C3G and primary IC-MPGN before year-end 2025.Seven abstracts were accepted for presentation at the upcoming American Society of Nephrology (ASN) Kidney Week, including new 52-week data from the Phase 3 VALIANT study that reinforce the robust and sustained efficacy profile of EMPAVELI in C3G and primary IC-MPGN. Paroxysmal nocturnal hemoglobinuria (PNH): The Company continues to see high patient compliance rates of 97%. Focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF): The Company expects to initiate two pivotal studies by year-end 2025, one in FSGS and one in DGF, two rare kidney diseases with significant complement pathway involvement and no approved therapies. Transforming the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

SYFOVRE: Generated $150.9 million in SYFOVRE U.S. net product revenue in the third quarter of 2025 Total injections grew 4% quarter-over-quarter.SYFOVRE remains the market leader in GA with total market share exceeding an estimated 60% and 52% of new patient starts during the quarter.Utilization of SYFOVRE free goods remained elevated during the quarter and impacted revenue by approximately $15 million.Delivered approximately 101K SYFOVRE doses to physician offices, including ~86K commercial doses and ~15K free goods doses. The Phase 2 study of SYFOVRE + APL-3007, a potential next generation treatment aimed at comprehensively blocking complement activity in the retina and choroid, is ongoing.
Business Update

Apellis and Sobi announced a capped royalty purchase agreement in July in which Apellis will receive up to $300 million in exchange for 90% of Apellis’ future ex-U.S. royalties for Aspaveli. Per the companies’ 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties.Under the terms of the royalty purchase agreement, Sobi acquired 90% of Apellis’ ex-U.S. royalties for Aspaveli for $275 million in cash. Apellis is also eligible for up to $25 million in milestone payments upon EMA approval of Aspaveli for C3G and IC-MPGN.The agreement is subject to defined caps tied to Aspaveli’s performance. Sobi retains 90% of ex-U.S. royalties until these caps are achieved, after which 100% of all ex-U.S. royalties revert to Apellis. Third Quarter 2025 Financial Results

Total Revenue

Total revenue was $458.6 million for the third quarter of 2025, which consisted of $150.9 million of SYFOVRE U.S. net product revenue, $26.8 million of EMPAVELI U.S. net product revenue, the $275.0 million upfront payment from Sobi in connection with the Aspaveli royalty purchase agreement, and $5.8 million in licensing and other revenue associated with the Sobi collaboration. Total revenue was $196.8 million for the third quarter of 2024, which consisted of $152.0 million of SYFOVRE U.S. net product revenue, $24.6 million in EMPAVELI U.S. net product revenue, and $20.3 million in licensing and other revenue associated with the Sobi collaboration.

Cost of Sales

Cost of sales was $24.5 million for the third quarter 2025, compared to $33.6 million for the same period in 2024. The decrease in cost of sales was primarily driven by lower volumes of product supplied to Sobi, a decrease in expenses incurred related to excess, obsolete or scrapped inventory and a decrease due to costs incurred in connection with cancellable purchase commitments. The decreases were partially offset by a higher volume from commercial sales and product provided under our patient assistance programs.

R&D Expenses

R&D expenses were $68.2 million for the third quarter of 2025, compared to $88.6 million for the same period in 2024. The decrease in R&D expenses was primarily driven by lower program-specific and non-program-specific external costs, and lower compensation and related personnel costs.

Selling, General and Administrative (SG&A) Expenses

SG&A expenses were $142.7 million for the third quarter of 2025, compared to $122.0 million for the same period in 2024. The increase in SG&A was primarily driven by higher general commercial activities, personnel costs and general and administrative expenses, including office expenses, travel expenses, insurance expenses, professional and consulting fees, and other expenses, partially offset by lower personnel costs and lower factoring fees.

Net Income

Apellis reported a net income of $215.7 million for the third quarter 2025, driven by the one-time $275.0 million upfront payment from Sobi in connection with the Aspaveli royalty purchase agreement. This compared to a net loss of $57.4 million for the same period in 2024.

Cash

As of September 30, 2025, Apellis had $479.2 million in cash and cash equivalents, compared to $411.3 million in cash and cash equivalents as of December 31, 2024. Based on its strong cash position, the Company elected to discontinue factoring its receivables during the quarter. Apellis now carries the incremental $80.6 million in receivables from the first three quarters of the year on its balance sheet and expects to realize cost savings of approximately $4.8 million on a go-forward annual basis. The Company continues to expect that its cash, combined with expected product revenues, will fund the business to profitability.

Conference Call and Webcast

Apellis will host a conference call and webcast to discuss its third quarter 2025 financial results and business highlights today, October 30, 2025, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the Company’s website. A replay of the webcast will be available for 90 days following the event.

About SYFOVRE® (pegcetacoplan injection)

SYFOVRE® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy secondary to age-related macular degeneration. By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system. SYFOVRE is approved in the United States and Australia.

About EMPAVELI®/Aspaveli® (pegcetacoplan)

EMPAVELI®/Aspaveli® (pegcetacoplan) is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases. It is the first treatment approved in the United States for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. EMPAVELI is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries globally, and is under investigation for other rare diseases.

About the Apellis and Sobi Collaboration

Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialization. Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.

U.S. Important Safety Information for SYFOVRE® (pegcetacoplan injection)

CONTRAINDICATIONS

SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.
WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Retinal Vasculitis and/or Retinal Vascular Occlusion Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay. Neovascular AMD In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration. Intraocular Inflammation In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE. Increased Intraocular Pressure Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed. ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.
Please see full Prescribing Information for more information.

U.S. Important Safety Information for EMPAVELI® (pegcetacoplan)

BOXED WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
EMPAVELI, a complement inhibitor, increases the risk of serious infections, especially those caused by encapsulated bacteria, such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

Complete or update vaccination for encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, unless the risks of delaying therapy with EMPAVELI outweigh the risks of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against encapsulated bacteria in patients receiving a complement inhibitor.
Patients receiving EMPAVELI are at increased risk for invasive disease caused by encapsulated bacteria, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious infections and evaluate immediately if infection is suspected.
Because of the risk of serious infections caused by encapsulated bacteria, EMPAVELI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the EMPAVELI REMS.

CONTRAINDICATIONS

Hypersensitivity to pegcetacoplan or to any of the excipientsFor initiation in patients with unresolved serious infection caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B WARNINGS AND PRECAUTIONS

Serious Infections Caused by Encapsulated Bacteria

EMPAVELI, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by encapsulated bacteria including Streptococcus pneumoniae, Neisseria meningitidis (caused by any serogroup, including non-groupable strains), and Haemophilus influenzae type B. Life-threatening and fatal infections with encapsulated bacteria have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of EMPAVELI treatment is contraindicated in patients with unresolved serious infection caused by encapsulated bacteria.

Complete or update vaccination against encapsulated bacteria at least 2 weeks prior to administration of the first dose of EMPAVELI, according to the most current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations considering the duration of therapy with EMPAVELI. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EMPAVELI therapy is indicated in a patient who is not up to date with vaccines against encapsulated bacteria according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. The benefits and risks of treatment with EMPAVELI, as well as the benefits and risks of antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by encapsulated bacteria.

Vaccination does not eliminate the risk of serious encapsulated bacterial infections, despite development of antibodies following vaccination. Closely monitor patients for early signs and symptoms of serious infection and evaluate patients immediately if an infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if these signs and symptoms occur. Promptly treat known infections. Serious infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of EMPAVELI in patients who are undergoing treatment for serious infections.

EMPAVELI is available only through a restricted program under a REMS.

EMPAVELI REMS

EMPAVELI is available only through a restricted program under a REMS called EMPAVELI REMS, because of the risk of serious infections caused by encapsulated bacteria. Notable requirements of the EMPAVELI REMS include the following:

Under the EMPAVELI REMS, prescribers must enroll in the program. Prescribers must counsel patients about the risks, signs, and symptoms of serious infections caused by encapsulated bacteria, provide patients with the REMS educational materials, ensure patients are vaccinated against encapsulated bacteria at least 2 weeks prior to the first dose of EMPAVELI, prescribe antibacterial drug prophylaxis if patients’ vaccine status is not up to date and treatment must be started urgently, and provide instructions to always carry the Patient Safety Card both during treatment, as well as for 2 months following last dose of EMPAVELI. Pharmacies that dispense EMPAVELI must be certified in the EMPAVELI REMS and must verify prescribers are certified.

Further information is available at www.empavelirems.com or 1-888-343-7073.

Infusion-Related Reactions

Systemic hypersensitivity reactions (eg, facial swelling, rash, urticaria, pyrexia) have occurred in patients treated with EMPAVELI, which may resolve after treatment with antihistamines. Cases of anaphylaxis leading to treatment discontinuation have been reported. If a severe hypersensitivity reaction (including anaphylaxis) occurs, discontinue EMPAVELI infusion immediately, institute appropriate treatment, per standard of care, and monitor until signs and symptoms are resolved.

Monitoring Paroxysmal Nocturnal Hemoglobinuria (PNH) Manifestations after Discontinuation of EMPAVELI

After discontinuing treatment with EMPAVELI, closely monitor for signs and symptoms of hemolysis, identified by elevated LDH levels along with sudden decrease in PNH clone size or hemoglobin, or reappearance of symptoms such as fatigue, hemoglobinuria, abdominal pain, dyspnea, major adverse vascular events (including thrombosis), dysphagia, or erectile dysfunction. Monitor any patient who discontinues EMPAVELI for at least 8 weeks to detect hemolysis and other reactions. If hemolysis, including elevated LDH, occurs after discontinuation of EMPAVELI, consider restarting treatment with EMPAVELI.

Interference with Laboratory Tests

There may be interference between silica reagents in coagulation panels and EMPAVELI that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, avoid the use of silica reagents in coagulation panels.

ADVERSE REACTIONS

Most common adverse reactions in adult patients with PNH (incidence ≥10%) were injection site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, pain in extremity, hypokalemia, fatigue, viral infection, cough, arthralgia, dizziness, headache, and rash.

Most common adverse reactions in adult and pediatric patients 12 years of age and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) (incidence ≥10%) were injection-site reactions, pyrexia, nasopharyngitis, influenza, cough, and nausea.

USE IN SPECIFIC POPULATIONS

Females of Reproductive Potential

EMPAVELI may cause embryo-fetal harm when administered to pregnant women. Pregnancy testing is recommended for females of reproductive potential prior to treatment with EMPAVELI. Advise female patients of reproductive potential to use effective contraception during treatment with EMPAVELI and for 40 days after the last dose.

Please see full Prescribing Information, including Boxed WARNING regarding serious infections caused by encapsulated bacteria, and Medication Guide.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Apellis Forward-Looking Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the results of the Company’s clinical trials for EMPAVELI, SYFOVRE, or any of its future products will warrant regulatory submissions to the FDA or equivalent foreign regulatory agencies; whether systemic pegcetacoplan will receive approval from foreign regulatory agencies for C3G and primary IC-MPGN; rate and degree of market acceptance and clinical utility of EMPAVELI, SYFOVRE and any future products for which we receive marketing approval will impact our commercialization efforts; whether the Company’s clinical trials will be completed when anticipated; whether results obtained in clinical trials will be indicative of results that will be generated in future clinical trials or in the real world setting; whether the period for which the Company believes that its cash resources will be sufficient to fund its operations; and other factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 28, 2025 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:
Tracy Vineis
[email protected]
617.420.4839

Investor Contact:
Eva Stroynowski
[email protected]
617.938.6229

APELLIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Amounts in thousands, except per share amounts)         September 30, December 31,    2025   2024  Assets     Current assets:     Cash and cash equivalents $479,171  $411,290  Accounts receivable, net  345,538   264,926  Inventory  122,819   81,404  Prepaid assets  31,560   18,368  Restricted cash  1,430   1,322  Other current assets  10,158   11,644  Total current assets  990,676   788,954  Non-current assets:     Right-of-use assets  19,720   16,083  Property and equipment, net  1,927   2,952  Long-term inventory  40,909   75,713  Other assets  5,491   1,349  Total assets $1,058,723  $885,051  Liabilities and Stockholders' Equity     Current liabilities:     Accounts payable $38,602  $38,572  Accrued expenses  140,322   140,184  Convertible senior notes  93,581   —  Current portion of lease liabilities  7,022   6,753  Total current liabilities  279,527   185,509  Long-term liabilities:     Long-term credit facility  361,091   359,489  Convertible senior notes  —   93,341  Lease liabilities  13,680   10,201  Other liabilities  3,257   7,972  Total liabilities  657,555   656,512  Commitments and contingencies (Note 11)     Stockholders' equity:     Preferred stock, $0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at September 30, 2025 and December 31, 2024  —   —  Common stock, $0.0001 par value; 200,000 shares authorized at September 30, 2025 and December 31, 2024; 126,500 shares issued and outstanding at September 30, 2025, and 124,495 shares issued and outstanding at December 31, 2024  12   12  Additional paid-in capital  3,357,583   3,267,201  Accumulated other comprehensive loss  (2,400)  (3,308) Accumulated deficit  (2,954,027)  (3,035,366) Total stockholders' equity  401,168   228,539  Total liabilities and stockholders' equity $1,058,723  $885,051         APELLIS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) (Unaudited) (Amounts in thousands, except per share amounts)           For the Three Months Ended September 30, For the Nine Months Ended September 30,   2025   2024   2025   2024   (Unaudited) (Unaudited) Revenue:        Product revenue, net$177,755  $176,571  $499,042  $518,782  Licensing and other revenue 280,823   20,259   304,827   50,057  Total revenue: 458,578   196,830   803,869   568,839  Operating expenses:        Cost of sales 24,531   33,557   72,517   76,867  Research and development 68,186   88,569   221,621   251,216  Selling, general and administrative 142,678   121,984   403,162   379,571  Operating expenses: 235,395   244,110   697,300   707,654  Net operating income/(loss) 223,183   (47,280)  106,569   (138,815) Loss on extinguishment of development liability —   —   —   (1,949) Interest income 4,376   2,889   9,641   9,377  Interest expense (11,279)  (12,532)  (33,480)  (28,857) Other income/(expense), net 37   70   18   (405) Net income/(loss) before taxes 216,317   (56,853)  82,748   (160,649) Income tax expense 602   592   1,409   876  Net income/(loss)$215,715  $(57,445) $81,339  $(161,525) Other comprehensive income/(loss):        Unrealized gain on pension benefits 137   —   137   —  Foreign currency translation 32   222   771   402  Total other comprehensive income 169   222   908   402  Comprehensive income/(loss), net of tax$215,884  $(57,223) $82,247  $(161,123)          Net income/(loss) per share        Basic earnings per share$1.71  $(0.46) $0.65  $(1.31) Diluted earnings per share$1.67  $(0.46) $0.65  $(1.31) Weighted-average shares used in calculating:        Basic earnings per share 126,424   124,234   125,971   123,698  Diluted earnings per share 130,067   124,234   129,653   123,698           

October 30, 2025 07:05 ET

 | Source:

Cartesian Therapeutics, Inc.

FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000 shares of the Company’s common stock with an exercise price of $8.85, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. On October 29, 2025, the Company issued to another employee an option to purchase an aggregate of 2,650 shares of the Company’s common stock with an exercise price of $8.20, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The first employee’s option vests as to 25% on October 27, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 27, 2029. The second employee’s option vests as to 25% on October 29, 2026, and then in three equal annual installments thereafter such that the option will be fully vested on October 29, 2029. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T currently being evaluated in a Phase 1 trial in patients with multiple myeloma. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
[email protected]

Media Contact:
David Rosen
Argot Partners
[email protected]

Cadence Design Systems NASDAQ: CDNS is a dominant player in a vital part of the semiconductor industry. It provides electronic design automation (EDA) software, which is critical for designing semiconductors.

Jerónimo Martins, SGPS, S.A. (OTCPK:JRONY) Q3 2025 Earnings Call October 30, 2025 5:00 AM EDT

Company Participants

Ana Virgínia - Chief Financial Officer

Conference Call Participants

William Woods - Sanford C. Bernstein & Co., LLC., Research Division
José Rito - Banco BPI, S.A., Research Division
António Seladas - A|S Independent Research

Presentation

Operator

Good day, and welcome to the Jerónimo Martins First 9 Months 2025 Results Conference Call. Today's conference is being recorded.

At this time, I would like to turn the conference over to Ms. Ana Luisa Virginia , Chief Financial Officer of Jerónimo Martins Group. Please go ahead, madam.

Ana Virgínia
Chief Financial Officer

Thank you, Sharon. Good morning, ladies and gentlemen, and thank you for joining this call dedicated to our first 9 months results. As usual, in our corporate website, you can find the results release, a slide presentation and a fact sheet for the period.

The first 9 months of 2025 continue to be defined by the ongoing global geopolitical uncertainty that is also shaping consumer sentiment and fostering a more cautious value-driven approach among shoppers. Against this challenging context, price remains at the heart of our strategy across all banners. Every team worked hard to uphold our promise of price leadership and to create an attractive quality assortment, securing customer preference and driving sales growth.

The reinforced commitment to cost discipline, operational efficiency and productivity paid off and ensure that EBITDA margins remained robust despite the tough combination of low basket inflation with high cost inflation in extremely competitive backdrops. Meanwhile, our ambitious CapEx program is being executed as planned, reaching EUR 816 million in the period with the opening of 274 new stores and the renovation of 170 locations.

The balance sheet kept its robustness, closing September with a net cash position, excluding capitalized leases

Recommended For You